BBIO vs CVS · rev $221.9M vs P/E 16, rev $402.07B
BridgeBio Pharma Inc (BBIO) versus CVS Health Corp (CVS) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
CVS Health Corp (CVS) is a healthcare plans company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported CVS revenue for 2025-12-31 was $402.07B. Net income was $1.77B. Revenue was up 7.8% from 2024-12-31 to 2025-12-31. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
BBIO currently screens at market cap $13.24B. CVS currently screens at market cap $86.20B and trailing P/E 16.3.
Not investment advice. Open the BBIO and CVS stock pages for the full models.
Not investment advice.